New drug HCB301 enters early human trials for tough cancers
NCT ID NCT06487624
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial is testing a new drug called HCB301 in 50 adults with advanced solid tumors or Hodgkin lymphoma that has come back or not responded to other treatments. The main goals are to check the drug's safety, find the right dose, and see if it shows any signs of shrinking tumors. Participants receive HCB301 by IV infusion, and researchers will monitor side effects and tumor response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HCB301 (a drug given by IV infusion)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors or Hodgkin lymphoma who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 50 participants, so it is primarily testing safety and dosing. The drug may not shrink tumors or may cause side effects, and it is too soon to know if it will be effective.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kaohsiung Medical University Chung-Ho Memorial Hospital
RECRUITINGKaohsiung City, Taiwan
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Prisma Health-Upstate
RECRUITINGGreenville, South Carolina, 29605, United States
-
Southern Medical University Zhujiang Hospital
RECRUITINGZhujiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The First Affiliated Hospital, Zhejiang University School of Medicine
RECRUITINGHangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Xuzhou Central Hospital
RECRUITINGXuzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Yantai Yuhuangding Hospital
RECRUITINGYantai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Zhejiang Provincial Cancer Hospital
RECRUITINGHangzhou, China
Contact Phone: •••-•••-•••• Email: •••••@•••••